Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614540 | 1.00 | CA1 (0.55) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL7902024 | 0.86 | CA1 (0.56) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL7973199 | 0.86 | CA1 (0.56) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL7898004 | 0.85 | CA1 (0.55) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL9471956 | 0.85 | CA1 (0.55) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL170233 | 0.83 | ALDH1A1 (0.65) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL614654 | 0.81 | CA1 (0.56) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL7998430 | 0.81 | TSHR (0.58) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL12633937 | 0.81 | CA1 (0.56) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL12633934 | 0.81 | CA1 (0.56) | CA1CA2ACHEALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG | 2012-02-16 | — | — | US | disclosed |
| US-8076489-B2 | 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| EP-1819686-B1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2305659-A1 | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| EP-1819686-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056471-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | CA1 3843/4885CA2 998/4885ACHE 805/4885 |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | ADRB2, ADRB1, ADRA2C | CA1 3843/4885CA2 998/4885ACHE 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.